The role of high-dose steroid therapy in Covid-19 pneumonia
| Autor: | Suna Kavurgacı, Figen Ozturk Ergur, Melahat Uzel Şener, Murat Yıldız, Ayperi Öztürk |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Mortality rate medicine.disease Gastroenterology Intensive care unit Hypoxemia law.invention Pneumonia Methylprednisolone Respiratory failure law Internal medicine Oxygen therapy medicine medicine.symptom business Dexamethasone medicine.drug |
| DOI: | 10.22541/au.162699286.68650358/v1 |
| Popis: | Introduction: Today, whereas hypoxemia and respiratory failure is the major challenging problem in the course of severe COVID-19 pneumonia, to control the disease at a mild-moderate stage or to stop the inflammation by recognizing the cytokine storm early should be the most prominent goal. We aimed to reveal the clinical efficacy and safety of short-term high-dose corticosteroids in severe COVID-19. Material and Methods: This retrospective observational study consisted of 54 patients who were given high-dose steroid (HDS (>250 mg/day methylprednisolone, 3 days.). Low-dose steroid (LDS) therapy (dexamethasone 8 mg ) was applied to all patients. HDS group was reviewed in terms of decreasing hospital mortality and preventing fibrosis development in follow-up. Results: During the observation period, out of 317 severe COVID-19 pneumonia hospitalized, HDS and LDS were administered to 54 and 216 patients, respectively. Higher body mass index, younger age, more oxygen need of patients at admission, and more need for advanced oxygen therapy during hospitalization were found in the HDS group (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|